Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
August 31, 2024 3:30 PM 2 min read

Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential

by Nabaparna Bhattacharya Benzinga Editor
Follow
NVO Logo
NVONovo Nordisk AS
$48.72-0.04%
Overview

Researchers are now suggesting that a drug for Type 2 diabetes and obesity might actually have anti-aging powers.

Harlan Krumholz of the Yale School of Medicine declared that semaglutide, marketed as Ozempic, could be a game-changer with benefits far beyond our wildest dreams after several groundbreaking studies revealed its unexpected potential, reported BBC.

Researchers have discovered that the drug might tackle a broad spectrum of ailments, including heart failure, arthritis, Alzheimer’s and even cancer.

“It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process,” Krumholz remarked at the European Society of Cardiology Conference 2024 on Friday, where the groundbreaking studies were unveiled.

Also Read: Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients

The new data has been published in several medical journals, including the Journal of the American College of Cardiology (JACC), which is edited by Krumholz.

“These groundbreaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health,” he said.

The studies, part of the Select trial, monitored over 17,600 people aged 45 and older who received either 2.4 mg of semaglutide or a placebo for over three years.

All participants were obese or overweight with cardiovascular disease but did not have diabetes. Researchers discovered that those taking the drug had a lower overall mortality rate, including deaths from cardiovascular issues and Covid-19, BBC noted.

People using the weight-loss drug were equally susceptible to contracting Covid but had a lower mortality rate from it — 2.6% of those on semaglutide died compared to 3.1% on the placebo.

While women saw a reduction in major adverse cardiovascular events, the drug consistently lowered the risk of cardiovascular issues for both sexes. It also alleviated heart failure symptoms and reduced inflammation in the body, regardless of weight loss.

The medication, available on prescription from the NHS, is known under the brand names Wegovy for obesity and Ozempic for diabetes.

It’s administered via injection and mimics the hormone GLP-1 to help users feel fuller and curb their appetite. Experts caution that it’s not a miracle solution or a substitute for healthy eating and exercise, and should be used under medical supervision.

Potential side effects include nausea, stomach upset, bloating, and gas, BBC added.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Also Read: 

  • Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
EquitiesNewsHealth CareMarketsGeneralDiabeteshealthcareOzempicwegovy
NVO Logo
NVONovo Nordisk AS
$48.72-0.04%
Overview
Comments
Loading...